Overview

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

Status:
Completed
Trial end date:
2017-05-12
Target enrollment:
Participant gender:
Summary
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Galderma R&D
Treatments:
Trifarotene